Russia has developed a personalized mRNA cancer vaccine, EnteroMix, which it plans to begin administering to patients in October 2025. The vaccine utilizes technology similar to that of COVID-19 mRNA vaccines, with AI-driven algorithms creating individualized mRNA blueprints based on patient genetic data, significantly reducing development time.

The Russian Federal Medical and Biological Agency (FMBA) announced the vaccine’s readiness for clinical use, citing 100% efficacy in early trials. Reports indicate the treatment effectively shrinks and eliminates tumors without major side effects. Trials covered multiple cancer types, including lung, breast, colorectal, pancreatic, and chemo-resistant cancers, with limited clinical application already underway in Russia.

FMBA head Veronica Skvortsova stated the vaccine successfully passed preclinical trials, demonstrating safety and high effectiveness. It targets specific tumors while sparing healthy tissue and is tailored to each patient’s RNA, offering a fully personalized therapy. Initial focus areas include colorectal cancer, with developments also underway for glioblastoma and melanoma.

The oncolytic vaccine was created by the Ministry of Health’s National Medical Research Radiology Centre in collaboration with the Engelhardt Institute of Molecular Biology. Its public launch occurred at the St Petersburg International Economic Forum (SPIEF 2025), where Russia highlighted medical research advancements. The government plans to offer the vaccine free of charge, integrating it into national healthcare strategy.

The development follows a three-step program: generating mRNA blueprints via AI algorithms, synthesizing therapeutic mRNA at the Gamaleya Center, and leveraging mRNA technology to train the immune system against cancer cells. Preclinical trials reported reduced tumor growth and minimized metastasis risks, with adaptability to address emerging oncological challenges.